Distinguishing Curable from Progressive Dementias for Defining Cancer Care Options

Cancers (Basel). 2023 Feb 7;15(4):1055. doi: 10.3390/cancers15041055.

Abstract

The likelihood of a diagnosis of dementia increases with a person's age, as is also the case for many cancers, including melanoma and multiple myeloma, where the median age of diagnosis is above 60 years. However, patients diagnosed with dementia are less likely to be offered invasive curative therapies for cancer. Together with analysis of diet and medication history, advanced imaging methods and genetic profiling can now indicate more about syndromes causing the neurological symptoms. Cachexia, malnutrition, dehydration, alcohol consumption, and even loneliness can all accentuate or cause the "3Ds" of dementia, delirium and depression. Many common drugs, especially in the context of polypharmacy, can cause cognitive difficulties resembling neurodegenerative disease. These syndromes may be reversed by diet, social and caregiver changes, and stopping potentially inappropriate medications (PIMs). More insidious are immune reactions to many different autoantigens, some of which are related to cancers and tumors. These can induce movement and cognitive difficulties that mimic Alzheimer's and Parkinson's diseases and other ataxias associated with aging. Paraneoplastic neurological syndromes may be reversed by directed immunotherapies if detected in their early stages but are best treated by removal of the causative tumor. A full genetic workup should be done for all individuals as soon as possible after diagnosis, to guide less invasive treatments suitable for frail individuals. While surgical interventions may be contraindicated, genetic profile guided immunotherapies, oral treatments, and radiation may be equally curative in a significant number of cancers.

Keywords: Alzheimer & Parkinson diseases; PIMs (potentially inappropriate medications); autoimmune encephalitis; cancer care team; cancer genetic profiling; conditions causing altered mental state; de-prescribing; dementia, delirium, depression (3Ds); immunotherapy in CRC; microsatellite instability (MSI/DNA mismatch repair (dMMR); neurological syndromes; non-surgical intervention in frail patients; polypharmacy.

Publication types

  • Review

Grants and funding

This research received no external funding.